Some Factors Affecting the Intraocular Pressure Reduction After Argon Laser Trabeculoplasty in Open‐angle Glaucoma

Bergeå, Bengt

doi:10.1111/j.1755-3768.1984.tb05796.x

Cited by 22 publications

(12 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Many studies have shown that IOP reduction is larger in exfoliation glaucoma than in POAG, 2,5,19,22,32,38 even after performing multivariate analyses to correct for differences in pre-ALT IOP between these two types of the disease. 3 There is no agreement as to whether the pressure-lowering effect of ALT is influenced by trabecular pigmentation or pigmentation grade, 3 -5,22,24,37,38 and we found no significant impact of either of those aspects in our investigation. However, it should be reiterated that the power of our study was low in this context, because only 7 patients had a non-pigmented trabecular meshwork.…”

Section: Discussioncontrasting

confidence: 54%

Effects of Argon Laser Trabeculoplasty in the Early Manifest Glaucoma Trial

Heijl

Peters

Leske

et al. 2011

American Journal of Ophthalmology

View full text Add to dashboard Cite

Methods: Patients randomized to the treatment arm of the EMGT received a standard treatment protocol (topical betaxolol hydrochloride followed by 360°ALT) and were then followed prospectively at 3-month intervals for up to 8 years. One eye per patient was included in the analyses. We investigated the relationship between pre-ALT IOP and subsequent IOP reduction, and other factors that might have influenced the effect of ALT, including stage of the disease, trabecular pigmentation, presence of exfoliation syndrome, and treating surgeon.Results: The mean pre-ALT IOP after betaxolol was 18.1 mmHg ± 3.9 (SD), and the mean short-term IOP reduction 3 months after ALT was 2.8 mmHg ± 3.9 (SD) (12.6%

show abstract

Section: Discussioncontrasting

confidence: 54%

Effects of Argon Laser Trabeculoplasty in the Early Manifest Glaucoma Trial

Heijl

Peters

Leske

et al. 2011

American Journal of Ophthalmology

View full text Add to dashboard Cite

show abstract

“…For PALT this is in accordance with earlier findings (BergeH 1984(BergeH , 1986; Bergei 8c Svedbergh 1992).…”

Section: Discussionsupporting

confidence: 91%

Primary argon laser trabeculoplasty vs pilocarpine II: Long‐term effects on intraocular pressure and facility of outflow

Bergeå

Bodin

Svedbergh

1994

Acta Ophthalmologica

Self Cite

View full text Add to dashboard Cite

In a prospective study 82 patients recently diagnosed with simple or capsular glaucoma were randomized to receive primary argon laser trabeculoplasty or pilocarpine treatment. A 2-year follow-up showed a better success rate in the laser group, with less need for additional therapy. The average intraocular pressure and peak pressure was lower and the daytime pressure variation was significantly less in the laser group. The better increase in facility of outflow in the laser group was not statistically significant. In capsular glaucoma, laser treatment resulted in a significantly lower average pressure than with medication. In simple glaucoma the effect was about the same in the two treatment groups. Increase in facility of outflow was significantly better in simple glaucoma than in capsular glaucoma. High initial intraocular pressure gave a significantly lower success rate. Primary argon laser trabeculoplasty as a single glaucoma treatment seems advantageous in comparison to medication with pilocarpine for regulating intraocular pressure.

show abstract

“…ALT is known to reduce IOP more in CG than in SG (Pohjanpelto 1981;Tuulonen & Airaksinen 1983;Bergei 1984;Svedbergh & Shenvood 1985). The greater IOP reducing effect in CG compared to that in SG in this study was not significant two months after the fvst treatment.…”

Section: Discussionmentioning

confidence: 95%

Primary argon laser trabeculoplasty vs. pilocarpine Short‐term effects

Bergeå

Svedbergh

1992

Acta Ophthalmologica

Self Cite

View full text Add to dashboard Cite

This is a prospective study of 82 newly discovered patients with simplex or capsular glaucoma from two centres, collected between 1984 and 1989 and selected at random for primary treatment by either laser or pilocarpine. Preliminary two-year follow-up shows that primary laser treatment gives a significantly higher number of patients where the intraocular pressure is successfully controlled. Primary argon laser trabeculoplasty has been carried out in 40 patients. The first treatment was given to either the upper or to the lower half of the trabecular meshwork. In the second treatment after one month the other half was treated. In both groups the first treatment gave the highest pressure reduction. The somewhat higher pressure reduction after upper treatment versus lower was insignificant. The degree of trabecular pigmentation did not influence the two month follow-up result, neither did the type of glaucoma. Of the eyes treated with laser, peripheral anterior synechiae could be seen in 18%. Acute intraocular pressure rises greater than 5 mmHg occurred in 21% of the eyes after the first treatment and in 37% after the second treatment. Pressure rises greater than 10 mmHg occurred in 5% after the first and in 10% after the second treatment. No pressure-lowering substances were given. Considering that 16% of the eyes had an intraocular pressure that was higher than baseline pressure even 6 h after either first or second treatment, it is recommended that a pressure-lowering medication on the day of treatment should be administered.

show abstract

Some Factors Affecting the Intraocular Pressure Reduction After Argon Laser Trabeculoplasty in Open‐angle Glaucoma

Cited by 22 publications

References 10 publications

Effects of Argon Laser Trabeculoplasty in the Early Manifest Glaucoma Trial

Effects of Argon Laser Trabeculoplasty in the Early Manifest Glaucoma Trial

Primary argon laser trabeculoplasty vs pilocarpine II: Long‐term effects on intraocular pressure and facility of outflow

Primary argon laser trabeculoplasty vs. pilocarpine Short‐term effects

Contact Info

Product

Resources

About